Position in TNGX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$46,287,932
New position
Shares Held
1,480,740
first reported quarter
Ownership
0.878%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
#31
of 247 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Polar Capital Holdings Plc holds $3,774,805,029 across 41 Biotechnology names. TNGX ranks #29 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ELVN |
Enliven Therapeutics, Inc.
|
6,430,636 | $326,354,777 | |
| 2 | XENE |
Xenon Pharmaceuticals Inc.
|
4,570,556 | $275,878,760 | |
| 3 | CYTK |
Cytokinetics Inc
|
2,253,649 | $191,988,358 | |
| 4 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
1,663,632 | $184,713,060 | |
| 5 | ARQT |
Arcutis Biotherapeutics, Inc.
|
6,606,945 | $173,234,097 | |
| 6 | ASND |
Ascendis Pharma A/S
|
616,908 | $164,541,701 | |
| 7 | BBIO |
BridgeBio Pharma, Inc.
|
2,063,609 | $153,697,598 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
482,751 | $145,322,533 |
All Filings in TNGX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $46,287,932 | 1,480,740 | Shares | Defined | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||